<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48588">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896128</url>
  </required_header>
  <id_info>
    <org_study_id>BRC-394</org_study_id>
    <nct_id>NCT01896128</nct_id>
  </id_info>
  <brief_title>Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke</brief_title>
  <official_title>Use of a Wakefulness-Promoting Agent (Armodafinil) Combined With Neuro-rehabilitation to Improve Neurological Recovery and to Reduce the Incidence of Disability in Patients Who Suffered a Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burke Rehabilitation Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Burke Rehabilitation Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Armodafinil is an FDA approved medication with wakefulness-promoting properties.  It is a
      relatively safe agent with interesting neurochemical effects on the catecholamine system,
      producing an improvement in cognitive function, particularly working memory in humans.  When
      combined with intensive task-related training, armodafinil may accelerate motor recovery in
      chronic stroke patients.

      The primary aim of this study is to determine whether administration of armodafinil during
      subacute post-stroke rehabilitation will augment cortical plasticity and enhance motor
      recovery.  The primary hypothesis suggests that cortical plasticity will be enhanced by
      armodafinil and, therefore, will induce an improvement in motor function and better
      performances on measures of motor control.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Fugl-Meyer Assessment of Sensorimotor Function from Baseline to Discharge</measure>
    <time_frame>Day 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Independence Measure (FIM) from Baseline to Discharge</measure>
    <time_frame>Day 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Fugl-Meyer Assessment of Sensorimotor Function from Baseline to Day 100</measure>
    <time_frame>Day 100</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Independence Measure (FIM) from Baseline to Day 100</measure>
    <time_frame>Day 100</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed 3-Minute Walk Test</measure>
    <time_frame>Day 1, Day 12, Day 50, Day 100</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale (NIHSS)</measure>
    <time_frame>Day 1, Day 12, Day 100</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-Hole Peg Test</measure>
    <time_frame>Day 1, Day 12, Day 50, Day 100</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Accident</condition>
  <condition>Hemiparesis</condition>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <arm_group_label>Armodafinil</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>inactive pill manufactured to mimic Armodafinil 150 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First clinical stroke, either cerebral infarction or intracerebral hemorrhage

          -  Severe hemiparesis as measured by a Fugl-Meyer motor scale score of 0-25

          -  Screening Motricity Index score of 0-83

          -  Date of stroke onset between 7 to 21 days prior to study inclusion

        Exclusion Criteria:

          -  Age less than 18

          -  Previous clinical stroke

          -  Pregnant and/or nursing patients

          -  Major psychiatric history, including psychosis and history of substance abuse

          -  Dementia

          -  Known CNS pathology such as brain tumor

          -  Significant language dysfunction or severe neglect that hinders comprehension,
             participation, and barrier to testing

          -  Seizures

          -  Left ventricular hypertrophy (LVH)

          -  Mitral valve prolapse (MVP)

          -  Severe chronic renal failure or severe hepatic failure

          -  History or current use of anti-epileptic medications, psychostimulants, or
             neuroleptics

          -  Current use of diazepam, phenytoin, propranolol, tricyclic antidepressants, steroidal
             contraceptives, cyclosporine, or theophylline
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasquale Fonzetti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Burke Rehabilitation Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Burke Rehabilitation Hospital</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Burke Rehabilitation Hospital</investigator_affiliation>
    <investigator_full_name>Pasquale Fonzetti, MD, PhD</investigator_full_name>
    <investigator_title>Associate Director, Memory Evaluation and Treatment Service</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>CVA</keyword>
  <keyword>cerebrovascular accident</keyword>
  <keyword>hemiparesis</keyword>
  <keyword>impairment</keyword>
  <keyword>motor recovery</keyword>
  <keyword>neuroplasticity</keyword>
  <keyword>nuvigil</keyword>
  <keyword>armodafinil</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
